SYM FINANCIAL Corp Acquires New Holdings in Stoke Therapeutics, Inc. $STOK

SYM FINANCIAL Corp bought a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 60,071 shares of the company’s stock, valued at approximately $1,562,000. SYM FINANCIAL Corp owned approximately 0.09% of Stoke Therapeutics as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of STOK. Quantbot Technologies LP bought a new stake in Stoke Therapeutics during the second quarter worth $34,000. KBC Group NV purchased a new stake in Stoke Therapeutics in the 1st quarter valued at $36,000. Sterling Capital Management LLC raised its position in Stoke Therapeutics by 849.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,833 shares of the company’s stock valued at $48,000 after buying an additional 1,640 shares during the last quarter. Western Wealth Management LLC bought a new position in Stoke Therapeutics during the 1st quarter valued at $55,000. Finally, EverSource Wealth Advisors LLC lifted its stake in Stoke Therapeutics by 195.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock valued at $60,000 after acquiring an additional 1,215 shares in the last quarter.

Insider Buying and Selling

In other news, Director Edward M. Md Kaye sold 12,567 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the transaction, the director directly owned 124,557 shares of the company’s stock, valued at $3,989,560.71. This represents a 9.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 1,051 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the sale, the insider owned 19,059 shares of the company’s stock, valued at approximately $498,583.44. The trade was a 5.23% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 34,594 shares of company stock worth $1,069,305. Insiders own 9.60% of the company’s stock.

Wall Street Analysts Forecast Growth

STOK has been the topic of a number of analyst reports. JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a report on Friday, August 21st. They set an “overweight” rating and a $40.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. The Goldman Sachs Group reissued a “buy” rating on shares of Stoke Therapeutics in a research report on Thursday, September 10th. Canaccord Genuity Group decreased their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $44.25.

Stoke Therapeutics Stock Up 2.6%

Shares of Stoke Therapeutics stock opened at $26.13 on Wednesday. Stoke Therapeutics, Inc. has a 1 year low of $20.32 and a 1 year high of $40.22. The stock has a fifty day moving average price of $27.78 and a 200-day moving average price of $30.97.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -3.52 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.